ASCO GU 2025

What's the role of Enzalutamide in radioligand therapy?

Milestones of ADT and ARPI treatment in the metastastic…

Darolutamide + ADT reduces risk of progression or death…

Hypo-gonadism bad for survival?

Testosterone Recovery

Mevrometostat - a new EZH2 inhibitor in mCRPC

Improved Survival with Enzalutamide + Lutetium

Final OS data for TALA + Enza

Durvalumab in UTUC

Radiation vs surgery in high risk prostate cancer

Darolutamide + ADT and Doetaxel improves survivas in…

Fish-oil supplement for pts on active surveillance

Radical Prostatectomy VS RT in HRPC

Final OS analyses

Mevrometostat + Enza: New option for mCRPC

Local radiotherapy of oligoprogressive mCRPC

OS in the TALAPRO-2 trial

Who benefits most from ARPIs?

Phase 2 Mevrometostat

ARPI for which patients?

MDT in OMPC

Testosterone Recovery after ADT and OS

Yuksek risk PCa da RP vs RT

Testosteron Geri Gelisi ve Sagkalim

Oligometastatik PCa da MDT

Hangi hastalarda ADT+ARPI

Enza+Lu ile artmis sagkalim

Exciting new substances - but don't over-estimate phase…

New data but no new conclusion

Triplet combination in RCC - there's no free lunch with…

Firstline Update Kidney Cancer

New data nccRCC

Prognostic and predictive biomarkers in mRCC: Looking…

New agents / new mode of actions

Proactive coaching of patients with TKI +/- IO therapy

Advanced Renal Cell Cancer: Adding more drugs does not…

AVION trial at mRCC

Casdatifan in refracting RCC

KIM-1 in mRCC

Cáncer de células renales avanzado: añadir más fármacos…

Neoadjuvant chemo-immunotherapy in UTUC: new evidence…

ADC + ICI - The future for MIBC?

Reassuring data on established ADCs and new insights in…

Exploratory analyses of pCR in NIAGARA: who benefits…

Durvalumab + Platinum-based chemotherapy shows…

HER2 - new marker for bladder preservation

New drugs in mUC: The active field of ADCs

Preliminary results of neoadjuvant chemoimmunotherapy…

EV-Pembro continues to be the standard for mTCC

Nivo adjuvant in MIBC - a new standard

Phase 2 Mevrometastat

A possible new standard for mUC

Sacituzumab Tirumotecan shows promising antitumor…

Updates neo/adjuvant therapy in MIBC

The role of ctDNA in bladder cancer

New FGFR3 inhibitor

Bladder-sparing approaches - are we there yet?

Adjuvant Nivo - independent from previous therapy

Promising combination for perioperative setting

ASCO GU 25 - Summary: Urothelial Cancer

ASCO GU 25 - Περίληψη: Ουροθηλιακός καρκίνος

Nuevos fármacos en mUC: El campo activo de las ADCs

Testicular cancer: Reinventing the wheel

Metastatik seminomda Primer RPLND